Intellectual Property
Lattice Biologics possesses patent pending applications protecting its core technology to create homing based extra cellular matrices. The provisional patent includes:
- Compositions of matter technology
- Pharmaceutical use of the technology
- Combination therapy of the technology
- Methods for manufacturing
Check back for updates.
- LATTICE BIOLOGICS LTD. COMPLETES DEBT TO EQUITY CONVERSION AND ISSUES SHARES FOR SERVICES 2017-07-17T16:32:53-0700
- LATTICE BIOLOGICS LTD. ANNOUNCES CHANGE IN DIRECTOR AND CHAIRMAN OF SCIENTIFIC ADVISORY BOARD 2017-07-06T16:26:08-0700
- LATTICE BIOLOGICS LTD. ANNOUNCES MOVE TO BELGRADE, MT 2017-06-26T09:20:27-0700
- LATTICE BIOLOGICS LTD. ANNOUNCES CHANGE TO LOCATION OF ITS ANNUAL GENERAL AND SPECIAL MEETING 2017-06-20T11:09:33-0700
- LATTICE BIOLOGICS LTD. ANNOUNCES COMPLETION OF TRANSACTION TO REDUCE ROYALTY AND DEBT OBLIGATIONS 2017-06-13T11:04:15-0700
- LATTICE BIOLOGICS LTD. RECEIVES MULTI-YEAR AMERICAN ASSOCIATION OF TISSUE BANKS RE-ACCREDITATION 2017-06-01T10:59:32-0700
- LATTICE BIOLOGICS LTD. APPOINTS CHIEF OPERATING OFFICER 2017-05-31T10:51:13-0700
- LATTICE BIOLOGICS LTD. REPORTS SECOND QUARTER 2017 HIGHLIGHTS 2017-05-30T17:12:04-0700
- LATTICE BIOLOGICS ANNOUNCES COMPLETION OF PRIVATE PLACEMENT 2017-05-15T08:44:29-0700
- LATTICE BIOLOGICS ANNOUNCES AGREEMENT TO SUCCESSFULLY REDUCE ROYALTY AND DEBT OBLIGATIONS 2017-04-26T09:15:59-0700
- LATTICE BIOLOGICS CLOSES FIFTH TRANCHE OF PRIVATE PLACEMENT AND EXTENDS FUNDING RAISE FOR AN ADDITIONAL 30 DAYS 2017-04-04T08:31:56-0700
- SERVICE PROVIDER LOYALTY REMAINS STRONG AS LATTICE BIOLOGICS ISSUES SHARES FOR SERVICES AND ANNOUNCES PLANNED DEBT-TO-EQUITY CONVERSION 2017-03-20T08:44:25-0700
- LATTICE BIOLOGICS EXTENDS PRIVATE PLACEMENT 2017-03-07T13:00:57-0700
- LATTICE BIOLOGICS LTD. REPORTS FIRST QUARTER 2017 HIGHLIGHTS 2017-03-01T18:00:11-0700
- LATTICE BIOLOGICS PARTICIPATES IN $300 MILLION PUBLIC-PRIVATE INITIATIVE, THE ADVANCED REGENERATIVE MANUFACTURING INSTITUTE (ARMI) 2017-02-28T18:52:12-0700
- LATTICE BIOLOGICS CLOSES FOURTH TRANCHE OF PRIVATE PLACEMENT ANNOUNCED ON JANUARY 19, 2017 2017-02-28T18:00:46-0700
- LATTICE BIOLOGICS CLOSES THIRD TRANCHE OF PRIVATE PLACEMENT ANNOUNCED ON JANUARY 19, 2017 2017-02-16T13:19:41-0700
- NOTICE OF LATTICE BIOLOGICS LTD. FIRST QUARTER 2017 FINANCIAL RESULTS CONFERENCE CALL 2017-02-14T12:58:26-0700
- LATTICE BIOLOGICS UPGRADED TO OTCQB VENTURE MARKET 2017-02-01T13:10:11-0700
- LATTICE BIOLOGICS LTD. REPORTS FOURTH QUARTER AND YEAR END 2016 HIGHLIGHTS 2017-01-30T05:14:55-0700
Upcoming Events
There are no upcoming events at this time.
-
Newsletter Subscription
Interesting news and advances in bioscience and technologies delivered to your inbox.
-
INVESTOR PRESENTATION
-
Biologic Allograft Products
Spinal & Demineralized Bone Matrix (DBM) Allografts
READ MORE
Lattice Biologics Ltd.
Lattice maintains headquarters, laboratory and manufacturing facilities in Belgrade, Montana as well as offices in Toronto Ontario.
-
Corporate HeadquartersP: +1.480.563.0800
-
512 E Madison Ave.F: +1.480.563.0810
-
Suite 101
-
Belgrade, MT 59714
- LATTICE BIOLOGICS LTD. COMPLETES DEBT TO EQUITY CONVERSION AND ISSUES SHARES FOR SERVICES 2017-07-17T16:32:53-0700
- LATTICE BIOLOGICS LTD. ANNOUNCES CHANGE IN DIRECTOR AND CHAIRMAN OF SCIENTIFIC ADVISORY BOARD 2017-07-06T16:26:08-0700
- LATTICE BIOLOGICS LTD. ANNOUNCES MOVE TO BELGRADE, MT 2017-06-26T09:20:27-0700
- LATTICE BIOLOGICS LTD. ANNOUNCES CHANGE TO LOCATION OF ITS ANNUAL GENERAL AND SPECIAL MEETING 2017-06-20T11:09:33-0700
- LATTICE BIOLOGICS LTD. ANNOUNCES COMPLETION OF TRANSACTION TO REDUCE ROYALTY AND DEBT OBLIGATIONS 2017-06-13T11:04:15-0700
- LATTICE BIOLOGICS LTD. RECEIVES MULTI-YEAR AMERICAN ASSOCIATION OF TISSUE BANKS RE-ACCREDITATION 2017-06-01T10:59:32-0700
- LATTICE BIOLOGICS LTD. APPOINTS CHIEF OPERATING OFFICER 2017-05-31T10:51:13-0700
- LATTICE BIOLOGICS LTD. REPORTS SECOND QUARTER 2017 HIGHLIGHTS 2017-05-30T17:12:04-0700
- LATTICE BIOLOGICS ANNOUNCES COMPLETION OF PRIVATE PLACEMENT 2017-05-15T08:44:29-0700
- LATTICE BIOLOGICS ANNOUNCES AGREEMENT TO SUCCESSFULLY REDUCE ROYALTY AND DEBT OBLIGATIONS 2017-04-26T09:15:59-0700
- LATTICE BIOLOGICS CLOSES FIFTH TRANCHE OF PRIVATE PLACEMENT AND EXTENDS FUNDING RAISE FOR AN ADDITIONAL 30 DAYS 2017-04-04T08:31:56-0700
- SERVICE PROVIDER LOYALTY REMAINS STRONG AS LATTICE BIOLOGICS ISSUES SHARES FOR SERVICES AND ANNOUNCES PLANNED DEBT-TO-EQUITY CONVERSION 2017-03-20T08:44:25-0700
- LATTICE BIOLOGICS EXTENDS PRIVATE PLACEMENT 2017-03-07T13:00:57-0700
- LATTICE BIOLOGICS LTD. REPORTS FIRST QUARTER 2017 HIGHLIGHTS 2017-03-01T18:00:11-0700
- LATTICE BIOLOGICS PARTICIPATES IN $300 MILLION PUBLIC-PRIVATE INITIATIVE, THE ADVANCED REGENERATIVE MANUFACTURING INSTITUTE (ARMI) 2017-02-28T18:52:12-0700
- LATTICE BIOLOGICS CLOSES FOURTH TRANCHE OF PRIVATE PLACEMENT ANNOUNCED ON JANUARY 19, 2017 2017-02-28T18:00:46-0700
- LATTICE BIOLOGICS CLOSES THIRD TRANCHE OF PRIVATE PLACEMENT ANNOUNCED ON JANUARY 19, 2017 2017-02-16T13:19:41-0700
- NOTICE OF LATTICE BIOLOGICS LTD. FIRST QUARTER 2017 FINANCIAL RESULTS CONFERENCE CALL 2017-02-14T12:58:26-0700
- LATTICE BIOLOGICS UPGRADED TO OTCQB VENTURE MARKET 2017-02-01T13:10:11-0700
- LATTICE BIOLOGICS LTD. REPORTS FOURTH QUARTER AND YEAR END 2016 HIGHLIGHTS 2017-01-30T05:14:55-0700
Latest Tweets
Site Map • Privacy Policy • Careers
© Copyright - Lattice Biologics Ltd. - All Rights Reserved